Published in Clin Chim Acta on January 30, 1998
Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism. J Clin Endocrinol Metab (2007) 1.38
Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. Afr Health Sci (2010) 1.15
Relationship between lipid and lipoprotein metabolism in trimesters of pregnancy in Nigerian women: Is pregnancy a risk factor? J Nat Sci Biol Med (2012) 0.75
An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science (2001) 8.73
The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem (1997) 4.55
Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation (1998) 4.39
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med (2001) 4.17
Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem (1999) 3.57
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature (1998) 3.48
Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem (1998) 3.27
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med (1998) 3.13
Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res (2000) 3.02
Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol (2001) 2.66
Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem (2000) 2.18
Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem (1997) 2.18
Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol (1999) 2.05
Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem (2000) 1.95
Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation (1999) 1.88
Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest (1995) 1.88
Cigarette smoking is associated with unhealthy patterns of nutrient intake: a meta-analysis. J Nutr (1998) 1.74
Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest (1995) 1.74
p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively. J Biol Chem (1999) 1.66
CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation (2000) 1.65
The orphan nuclear receptor ROR alpha is a negative regulator of the inflammatory response. EMBO Rep (2001) 1.64
Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem Biophys Res Commun (2004) 1.61
Transcriptional control of adipogenesis. Curr Opin Cell Biol (1998) 1.52
PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes (2001) 1.50
Antimicrobial activity of flavonoids from leaves of Tagetes minuta. J Ethnopharmacol (1997) 1.49
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest (2001) 1.47
Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis (1987) 1.47
Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem (1990) 1.46
PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans (2006) 1.44
An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J Neurochem (1990) 1.43
Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation (1996) 1.43
Lipid traffic between high density lipoproteins and Plasmodium falciparum-infected red blood cells. J Cell Biol (1991) 1.43
The use of monoclonal antibodies to localize the low density lipoprotein receptor-binding domain of apolipoprotein B. J Biol Chem (1989) 1.41
Distribution of lipid variables in subjects in Belfast, Northern Ireland and Taiyuan, P R China. Atherosclerosis (1993) 1.39
Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science (1996) 1.39
The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem (1998) 1.38
PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett (1998) 1.38
Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. Circ Res (2005) 1.37
Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol (1999) 1.35
Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol (1995) 1.35
Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J Neurochem (1992) 1.32
Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles. Biochem Biophys Res Commun (1987) 1.30
Use of bacterial expression cloning to localize the epitopes for a series of monoclonal antibodies against apolipoprotein B100. J Biol Chem (1990) 1.30
Cloning and sequencing of cDNAs encoding the human hepatocyte nuclear factor 4 indicate the presence of two isoforms in human liver. Gene (1994) 1.26
Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol (2000) 1.26
Circadian and glucocorticoid regulation of Rev-erbalpha expression in liver. Endocrinology (2000) 1.24
Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis (1996) 1.22
Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest (1996) 1.22
Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalpha. J Biol Chem (2000) 1.21
Transcriptional regulation of apolipoprotein A-I gene expression by the nuclear receptor RORalpha. J Biol Chem (1997) 1.18
Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. J Biol Chem (2001) 1.17
Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation (1996) 1.17
Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem (1994) 1.17
PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation (2001) 1.12
The epitopes of apolipoprotein A-I define distinct structural domains including a mobile middle region. J Biol Chem (1991) 1.12
Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res (1992) 1.10
Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. J Lipid Res (1989) 1.09
Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes. J Cell Biol (1994) 1.08
Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med (2000) 1.07
An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer. Cell Mol Life Sci (1999) 1.07
Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element. Mol Endocrinol (1999) 1.07
In vivo metabolism of apolipoprotein A-I on high density lipoprotein particles LpA-I and LpA-I,A-II. J Lipid Res (1991) 1.06
Black-white differences in serum Lp(a) lipoprotein levels. Clin Chim Acta (1987) 1.05
Coronary heart disease: reducing the risk: a worldwide view. International Task Force for the Prevention of Coronary Heart Disease. Circulation (1999) 1.05
Increased triglyceride levels in shift workers. Am J Med (1992) 1.05
PPARS in inflammation, atherosclerosis and thrombosis. J Cardiovasc Risk (2001) 1.04
Production of antimicrobials by Bacillus subtilis MIR 15. J Biotechnol (1992) 1.04
Leptin response to carbohydrate or fat meal and association with subsequent satiety and energy intake. Am J Physiol (1999) 1.04
Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipidol (2001) 1.03
The role of the orphan nuclear receptor Rev-Erb alpha in adipocyte differentiation and function. Biochimie (2005) 1.03
Antimicrobial activity determined in strains of Bacillus circulans cluster. Folia Microbiol (Praha) (1993) 1.02
Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response. Circulation (1999) 1.01
Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Témoins sur 'Infarctus du Myocarde. J Lipid Res (1996) 1.01
Complete atherosclerosis regression after human ApoE gene transfer in ApoE-deficient/nude mice. Arterioscler Thromb Vasc Biol (2000) 1.01
A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity. Mol Endocrinol (1999) 1.00
Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids. J Clin Invest (1998) 1.00
Soccer players under regular training show oxidative stress but an improved plasma antioxidant status. Clin Sci (Lond) (1999) 0.99
Human apolipoprotein A-IV binds to apolipoprotein A-I/A-II receptor sites and promotes cholesterol efflux from adipose cells. J Biol Chem (1990) 0.99
Effects of Pinus pinaster and Pinus koraiensis seed oil supplementation on lipoprotein metabolism in the rat. Lipids (1999) 0.99
Magnetic properties of ZnO nanoparticles. Nano Lett (2007) 0.98
Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. Etude Cas Témoin sur l'Infarctus du Myocarde. J Lipid Res (1995) 0.98
Immunoelectron microscopy of low density lipoproteins yields a ribbon and bow model for the conformation of apolipoprotein B on the lipoprotein surface. J Lipid Res (1995) 0.97
Effects of gender and menopausal status on plasma lipoprotein subspecies and particle sizes. J Lipid Res (1996) 0.96
Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol (1997) 0.96
Bovine brain endothelial cells express tight junctions and monoamine oxidase activity in long-term culture. J Neurochem (1989) 0.95
Low-density lipoprotein receptor on endothelium of brain capillaries. J Neurochem (1989) 0.95
Peroxisome proliferator-activated receptor activators inhibit oxidized low-density lipoprotein-induced endothelin-1 secretion in endothelial cells. J Cardiovasc Pharmacol (2002) 0.95
Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor. J Biol Chem (1997) 0.95
Plasma apolipoprotein concentrations in young adults with a parental history of premature coronary heart disease and in control subjects. The EARS Study. European Atherosclerosis Research Study. Circulation (1994) 0.94
Simultaneous measurement of plasma apolipoproteins A-I and B by electroimmunoassay. Clin Chem (1982) 0.94
Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation. J Lipid Res (1999) 0.94
Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J Biol Chem (2001) 0.93
Effects of postprandial lipemia on plasma cholesterol metabolism. J Clin Invest (1985) 0.93
Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. J Lipid Res (2000) 0.93
Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z Kardiol (2001) 0.93
Influence of serum amyloid A on cholesterol esterification in human plasma. Biochim Biophys Acta (1989) 0.92
Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages. J Lipid Res (2005) 0.92
Cutaneous xanthoma in association with paraproteinemia in the absence of hyperlipidemia. J Clin Invest (1989) 0.92